Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma

Journal of Clinical Oncology

Volumn 27, Issue 6, 2009, Pages 904-910

  Tsimberidou, Apostolia Maria ^a   Wen, Sijin ^a   McLaughlin, Peter ^a   O'Brien, Susan ^a   Wierda, William G ^a   Lerner, Susan ^a   Strom, Sara ^a   Jfreireich, Emil ^a   Medeiros, L Jeffrey ^a   Kantarjian, Hagop M ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; LACTATE DEHYDROGENASE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA BASE; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG CANCER; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SECOND CANCER; SENESCENCE; SEX DIFFERENCE; SKIN CANCER; SURVIVAL RATE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM; UNITED STATES; YOUNG ADULT;

EID: 60949087189     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.5398     Document Type: Article

References (24)

1. Manusow D, Weinerman BH: Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 232:267-269, 1975
2. Greene MH, Hoover RN, Fraumeni JF Jr: Subsequent cancer in patients with chronic lymphocytic leukemia: A possible immunologic mechanism. J Natl Cancer Inst 61:337-340, 1978
3. Cheson BD, Vena DA, Barrett J, et al: Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 17:2454-2460, 1999
4. Rai K, Patel DV: Chronic lymphocytic leukemia, in Hoffman R (ed): Hematology: Basic Principles and Practice (ed 3). Philadelphia, PA, Churchill Livingstone, 2000, pp 1350-1363
5. Tsimberidou AM, Wen S, O'Brien S, et al: Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol 25:4648-4656, 2007
6. Keating MJ, Kantarjian H, O'Brien S, et al: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44-49, 1991
7. Keating MJ, O'Brien S, Kantarjian H, et al: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878-2884, 1993
8. O'Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695-1700, 1993
9. O'Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001
10. Tsimberidou AM, Keating MJ, Giles FJ, et al: Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100:2583-2591, 2004
11. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005
12. McLaughlin P, Hagemeister FB, Rodriguez MA, et al: Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27:37-41, 2000
13. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
14. McLaughlin P, Liu N, Poindexter N, et al: Rituximab plus GM-CSF for indolent lymphoma. Proceedings of the 9th International Conference on Malignant Lymphomas, Lugano, Switzerland. Ann Oncol 2005 (suppl 5; abstr 104)
15. Cheson BD, Bennett JM, Grever M, et al:
16. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
17. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
18. Liu M, Scheurer ME, Bondy ML, et al: Extension of the cohort analysis for genetic epidemiology program to assess excess risk of cancer. Proceedings of the Joint Statistical Meetings American Statistical Association 2546-2550, 2007 (abstr)
19. Hamblin TJ: Richter's syndrome: The downside of fludarabine? Leuk Res 29:1103-1104, 2005
20. Van Den Neste E, Michaux L, Layios N, et al: High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol 83:356-363, 2004
21. Hawkins MM, Wilson LM, Burton HS, et al: Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 88:270-278, 1996
22. Tam CS, O'Brien S, Wierda W, et al: Seventy percent of complete responders remain in continuous remission: Five-year follow-up of 300 patients treated with fludarabine, cyclophosphamide, and rituximab (FCR) as initial therapy of CLL. J Clin Oncol 25:359s, 2007 (suppl; abstr 7008)
23. Travis LB, Rabkin CS, Brown LM, et al: Cancer survivorship: Genetic susceptibility and second primary cancers-Research strategies and recommen-dations. J Natl Cancer Inst 98:15-25, 2006
24. Travis LB, Curtis RE, Hankey BF, et al: Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 84:1422-1427, 1992